“A 2026 study found elevated SRPX2 in CKD patient kidney and serum samples and in mouse renal-fibrosis models; deleting Srpx2 attenuated kidney injury and fibrosis, while SRPX2 interaction with IRP1 disrupted iron regulation and iron dextran supplementation alleviated UUO-induced renal fibrosis.”

Checks out so far. 2 hold up so far.

0.9218 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.92, strongly supported · not yet reviewed by anyone else “A 2026 study found elevated SRPX2 in CKD patient kidney and serum samples and in mouse renal-fibrosis models; deleting Srpx2 attenuated kidney injury and fibrosis, while SRPX2 interaction with IRP1…” https://galedra.org/investigations/01a0eadc-776b-707f-a394-29880799d857

“SRPX2 expression was elevated in CKD patient kidney and serum samples and in experimental renal-fibrosis models, while global or tubular-epithelial deletion of Srpx2 attenuated kidney injury and fibrosis in mice.”

Supported · 0.9601 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card

“In experimental renal fibrosis, SRPX2 interacted with IRP1 and disrupted iron-regulatory signaling, and iron dextran supplementation alleviated UUO-induced renal fibrosis.”

Supported · 0.9601 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card